Nanopharmacia Group and FUCAM (Breast Cancer Foundation) -institution that attends more cases at national level and national leader in Mexico and Latin America-, signed an alliance at the ASCO Chicago 2019 Congress to apply technology in genomic medicine, which will allow testing for the BRCA1 and BRCA2 genes, where mutations susceptible to hereditary breast cancer will be identified through blood and DNA analysis.
These tests will be applied to women with a family history or with a specific type of cancer, with which it will be possible to prevent it by detecting the causal gene and implementing clinical care strategies such as close monitoring, chemoprophylaxis or risk-reducing surgery.
Dr. Horacio Astudillo de la Vega, president of the administrative and scientific board of the Nanopharmacia Group, said that breast cancer cases will increase globally by 15 percent over the next few years and, as the adult population grows, the number of cases will increase. number of patients that will develop cancer, so this disease will continue to occupy the first place in mortality among women.
In Mexico it is estimated that each year two million women reach the risk age for breast cancer, which is 40 years old, and which is increased by the current urban lifestyle:
a) They start pregnancies late.
b) For their work or activities do not breastfeed their children.
c) They consume alcohol and tobacco.
d) They are sedentary.
e) Their diet consists mostly of junk food and high in fats and sugars.
f) They are overweight.
g) They use indiscriminately female hormones.
Given this panorama, it is necessary to apply new preventive schemes that privilege early diagnosis; For this, the application of early breast cancer tests is essential to accurately determine the type of neoplasia that patients suffer and, as a consequence, offer personalized treatment.
Nanopharmacia Group, through its division 'Diagnostics', will perform the genomic tests that will be obtained through blood or saliva samples. The complexity and personalization of these analyzes allows that, in more than 50 percent of the time, the doctor chooses a medicine more appropriate for his patient, because the one that originally had prescribed could not work or harm.
Dr. Astudillo said that a model of prevention of this type would help save the lives of 500 women each year and thus begin to stop the figure of 5 thousand deaths per year, which, as he warned, has a tendency to continue increasing the number of deaths from this disease.
“For people who can not afford these treatments, an important alliance has been made with FUCAM to offer current genomic medical technology and give new hope to Mexican women who are diagnosed or have a family history of the disease,” Astudillo concluded. Vega